Antide is the decapeptide N-Ac-D-Nal(2),D-Phe(pCl),D-Pal(3),Ser,Lys(Nic),D-Lys(Nic),LeuLys(iPr),Pro, D-Ala-NH2 [Nal(2) represents 3-(2-naphthyl)alanine; Phe(p-Cl) represents 3-(4-chlorophenyl)alanine; Pal(3) represents 3-(3pyridyl)alanine; Lys(Nic) represents Ne-nicotinoyllysine; Lys-(iPr) represents N6-isopropyllysine], which is an antagonist of luteinizing hormone-releasing hormone (LHRH), which has high antiovulatory activity, releases negligible histamine, and is scheduled for scale-up, safety testing, and evaluation in the experimental primate and in clinical medicine. Thirty-five more peptides were synthesized, designed on antide with variations in positions 5-8. Of these, N-Ac-D-Nal(2),D-Phe(pCl), D-Pal(3),Ser,Lys(Pic),cis-D-Ala(PzAC),Leu,Lys(iPr),ProD-Ala-NH2 [Lys(Pic) represents N6-picoloyllysine; Ala(PzAC)
,ug vs. 36% per 0.5 ,ug and 100% per 1.0 pug. Antide showed significant (P < 0.001) duration of action when injected at a dose of 10 pug 44 hr before i jection of 50 ng of the agonist Antide showed oral antiovulatory activity at 600 pg (73%) and at 1200 pg (100%) with negligible difference between water and corn oil oral formulations.
We have synthesized and bioassayed antagonists of luteinizing hormone-releasing hormone (LHRH) with high potency and diminished activity to release histamine (1) . Our designs featured N6-nicotinoyl-D-lysine [D-Lys(Nic)] in position 6 and NE-isopropyllysine [Lys(iPr)] in position 8 . We avoided the basic D-Arg6, which, in combination with Arg8 and a cluster of hydrophobic aromatic amino acid residues at the N terminus, has been implicated in the release of histamine (2) (3) (4) .
Other reductions of anaphylactoid activity include increasing the distance between the positive charges in positions 6 and 8 by Args and a neutral residue in position 6 as in [N-Ac-D-Nal(2)1,D-Phe(pCl)2,D-Pal(3)3,Arg5,D-4(p-methoxybenzoyl)-2-aminobutyric acid6,D-Ala'0]LHRH [Nal (2) represents 3-(2-naphthyl)alanine; Phe(pCl) represents 3-(4-chlorophenyl)alanine; Pal(3) represents 3-(3-pyndyl)alanine] by Rivier et al. (5) and [N-Ac-D-Nal(2)',D-Phe(aMepCl)2,D-Trp3,Arg5,D-Tyr6,D-Ala10]LHRH [Phe(aMepCl) represents 2-methyl-3-(4-chlorophenyl)alanine] by Roeske et al. (6) . Further modifications in position 6 are reductive alkylation of D-Lys6 by Hocart et al. (7) and incorporation ofN,N-diethylhomoarginine by Nestor et al. (8) and of citrulline or homocitrulline by Bajusz et al. (9) . The cyclic analogs recently synthesized by Rivier et al. (10) did not show any lowering in histamine release compared to the linear counterparts.
From our 52 peptides (1) , 2 were chosen as models for further design. [N-Ac-D-Nal (2) Herein are results from analogs with acylated aminocyclohexylalanine residues in position 6, from analogs in which Leu' has been substituted with other neutral residues, from a comparison of Lys(iPr)8 vs. N8-isopropylornithine at position 8 [Orn(iPr)8], and from tests on oral activity and duration of activity, oral and s.c.
MATERIALS AND METHODS Synthesis. The peptides were synthesized by the solidphase method (1, 11) .
Purification. The peptides were purified by silica gel chromatography with the solvent system 1-butanol/acetic acid/water, 4:1:2 (vol/vol), or 4:1:5 (vol/vol), upper phase followed by gel filtration on Sephadex G-25. Alternatively, purification was achieved by gel filtration on Sephadex G-25 followed by chromatography on Sephadex LH-20 with the solvent system water/1-butanol/acetic acid/methanol, 90: 10:10:8 (vol/vol).
The purity was checked by HPLC, TLC, and amino acid analysis. HPLC was performed on a Waters Associates instrument equipped with a model 660 solvent programer and either a uBondapak C18 or a Vydac C18 analytical column. Single peaks were obtained at flow rates of 2 or 1.5 ml/min using linear gradients of increasing acetonitrile in 0.01 M KH2PO4 (pH 3).
Abbreviations: LH, luteinizing hormone; LHRH, LH-releasing hormone; AOA, antiovulatory activity; Lys(iPr), N6-isopropyllysine; Nal(2), 3- §To whom reprint requests should be addressed. 8236 The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. TLC was done on E. Merck 0.25-mm silica gel plates and single spots were obtained in at least four different solvent systems as determined by the chlorine/o-toluidine test.
The amino acid analyses were carried out on a Beckman 118 CL amino acid analyzer after hydrolysis at 110°C in constant-boiling HCl for 24 hr. Unnatural amino acids were verified and, with the exception of Pal(3), were not quantified. All values for amino acid ratios were correct within the limits of experimental error.
Biological Assays. The AOA in rats was determined as described (12) . The wheal test was also performed as reported (1) . The in vitro histamine release test was conducted on rat mast cells as reported (3, 4) . The results are expressed as ED50-i.e., the concentration in ,g/ml that releases 50o of the total releasable histamine.
For the determination of duration of action, the antagonist was administered s.c. or orally to 26-day-old female rats at a specific time before administration of the agonist [D-
The serum levels of rat luteinizing hormone (LH) and rat folliclestimulating hormone (FSH) were then measured 2 hr after the agonist administration by RIA. The oral administration was done through force-feeding with feeding tubes.
RESULTS AND DISCUSSION
AOA and Histamine Release Data. Table 1 shows data on AOA and histamine release for analogs containing acylated aminocyclohexylalanine residues. For the analogs with Lys(Nic)5, D-Ala(NAC)6, 1 and 2 [Ala(NAC) represents 3-(4-nicotinoylaminocyclohexyl)alanine], analog 2, with cis-D-Ala(NAC)6, is somewhat more active, 100%o vs. 70% AOA at 1 ,ug. Analogs 7 and 8, with Lys(Nic)5, D-Ala(PzAC)6 [Ala(PzAC) represents 3-(4-pyrazinylcarbonylaminocyclohexyl)alanine], show the opposite order of activity. The trans residue has the higher AOA, 88% vs. 25% at 1 ,tg.
Analogs 3 and 4, with Lys(Pic)5, trans-and cis-Ala(PAC)6 [Ala(PAC) represents 3-(4-picolinoylaminocyclohexyl)alanine], are equipotent (50%o and 54% AOA at 0.5 ,ug, respectively), whereas in the case of Lys(Pic)5, trans-and cis-Ala(PzAC)6 the cis compound is more than twice as active. The former, analog 5, is about as potent as analogs 3 and 4 (44% at 0.5 ,tg), whereas the latter, analog 6, has 100M, 73%, and 29% AOA at 0.5, 0.25, and 0.125 ug, respectively. The high potency analog 6 is unique in comparison with the low activity of the structurally similar analog 8.
Analog 9 has cis-Ala(PzAC)5, D-Lys(Pic)6, and, interestingly, although residues 5 and 6 are reversed, retains the high potency of analog 6, 90%o and 67% at 0.5 and 0.25 ,ug, respectively.
As for histamine release, all analogs tested in vitro have lower ED values than the parent compounds. The ED50 values range from about 30 to about 60 ,g/ml compared to >300 and 93 + 11 ,ug/ml for antide and analog 10. The tests for wheal response show a range from 99.5 to 129.6 mm2/10 ,ug, which is similar to antide (132.7 mm2/10 ,ug) and analog 10 (123.0 mm2/10 pg). The lack of correlation between the two tests may primarily reflect assay variation.
In summary, for the analogs with Lys(Nic)5, incorporation of aminocyclohexylalanine derivatives in position 6 resulted in substantial increase in in vitro histamine release and unchanged or lowered AOA. For the Lys(Pic)s analogs with the same substitutions there was lowering of AOA potency in all cases except one, where a considerable increase was observed. The combination Lys(Pic)5 and cis-D-Ala(PzAC)6 evidently possesses some beneficial structure. Histamine release for the Lys(Pic)5 analogs was increased by 50-100%.
The results from substitutions in position 7 of analog 10 are presented in Table 2 . This position allows some structural freedom, although none of the peptides shows higher AOA than analog 10. Analogs 12, 14, and 16, with Ail', Val7, and Abu', are equipotent with analog 10. Analog 16, with the straight-chain Abu', is slightly more potent than analogs 13 and 15, with Nle' and Nva7, respectively, which should more closely resemble the natural Leu'.
For compound 17, with the small Ala7, the AOA decreased to 60% at 0.5 ,ug. Incorporation of Trp7, which is the natural residue in chicken II, salmon, and lamprey LHRHs (13-15), gave analog 18, with only 10%o AOA at 0.5 gg. Trp7 may be too large considering the size of the adjacent D-Lys(Pic)6 and Lys(iPr)8.
The most interesting feature of Table 2 is the in vitro histamine release data. The three analogs with AOA potency similar to that of analog 10 show markedly diminished histamine release. The ED50 values for analogs 12, 14, and 16 are> 300, 213 + 30, and 273 ± 27 ,g/ml, respectively-i.e., a 2to 3-fold decrease in histamine release is achieved by Medical Sciences: Lj'ungqvist et al. small changes in side-chain structure. Also, the wheal response is diminished for all analogs compared to that of analog 10. It was noted earlier (1) that whether Lys(iPr) or Orn(iPr) is the best substituent in position 8. is sequence dependent. To further investigate this aspect, the Orn(iPr)8 analogs corresponding to some of the best. peptides were synthesized and tested. The results in Table 3 indicate that Lys(iPi)8 may be better. For two of the pairs, analogs 10 and 19 and analogs 12 and 21, Lys(iPr)8 and Orn(iPr)8 are about equivalent. For the other three pairs, the analogs with Lys(iPr)8 are more active, but the differences are not large. The largest difference is for the pair with Val7, where the Lys(iPi)8 analog, 14, showed 90% AOA at 0.5 ug vs. 57% for the Orn(iPr)8 analog, 20.
Analog 19 was tested in vitro for histamine release. The ED50 value is 42 + 3.1 Ag/ml-2-i.e., the histamine release is 2-fold that of the analog with one more CH2 unit. The wheal response did not change conspicuously except for the Ail7, Orn(iPr)8 analog, 21, which had the low value of 78.6 ± 4.5 ,ug/ml compared to the Lys(iPr) analog, 12, which had 97.9 2.9,g/ml. Duration of Action. Table 4 shows the duration of action of antide and two analogs. When antide was injected 44 hr before injection of50 ng of [D-Qal(3)6]LHRH, a superagonist, at doses of 3, 10, and 30 ,ug, significant reductions in serum LH were observed at the two higher doses. The LH decreased from 113 ± 11 to 46 ± 12 and 5 0.7 ng/ml. Serum FSH was also decreased, most significantly from about 3000 to about 300 ng/ml at 30 ,g.
Analog 24 and analog 6 were similarly injected .24 hr before injection of the agonist. Analog 24 showed high activity, reducing the LH level to 19 ± 4, 3 0.4, and 0.3 ± 0.03 ng/ml at doses of 3, 10, and 30 ,ug, respectively. The corresponding figures for analog 6 are 42 ± 7, 15 ± 3, and 3.4 2 ng/ml. This is interesting since in the AOA assay analog 6 is considerably more potent,. 73% at 0.25 ,ug vs. 45% at 0.5 ,ug. Perhaps analog 6 is enzymatically degraded faster than analog 24. The long duration of action of these analogs when injected s.c. may also be due to "depot" effects at the site of injection.
Oral Activity. Table 5 shows the duration ofaction of antide after oral administration. Forty-eight hours after administration of 100 or 300 ,ug of antide, there were significantly reduced levels of LH that had been released by 5 ng of [D-Qal(3)6]LHRH administered s.c. Reductions from 21 ± 3 to 4 ± 0.8 and 8 ± 2 ng/ml, respectively, were observed. The results are about the same in the -24-hr experiment (9 ± 2 and 6 ± 0.3 ng/ml). Antide appears to possess considerable resistance toward degrading enzymes. When antide was given 2 hr before the agonist, a strong decrease in LH levels was observed. At a dose of 30 jig, a significant lowering ofthe LH level (to 6 ± 1 ng/ml) was seen. At 100 and 300 tug, the levels were 1 ± 0.3 and 0.4 + 0.4 ng/ml-i.e., very low levels. When 10 ng of agonist was used, the results were qualitatively very similar.
For comparison, the last three entries in Table 5 are from experiments with [Ned-Ac-D-Phe(pCl)1'2,D-Trp3,D-Arg6,D-Ala'0]LHRH, 25, an analog that has been reported to have oral activity (16) . These data show that antide is more active than analog 25, since a dose of 30 ,ug given 2 hr before administration of the agonist reduced the LH level from 44 ± 4 to 22 + 4 ng/ml (P < 0.01). The value for analog 25 is 39 + 6 ng/ml (not significant). At 100 ,4g, the corresponding numbers are 7 + 3 (P < 0.001) and 26 ± 7 (P < 0.05). The FSHI levels were, in general, reduced when antide was administered at -2 hr at 100 or 300 ,ug. The results in Table 6 show that there is no significant difference between administration of antide in water or in corn oil.
Antide has also been tested orally in the AOA assay ( Table  7) . The AOA values at 300,600, and 1200,ug are 18%, 73%, and 100%o, respectively. When expressed as the number ofrats that ovulated/total number ofrats, the numbers are 9/11, 3/11, and 0/11. For analog 25, the numbers 9/11, 4/11, and 0/11 have been reported at doses of 500, 1000, and 2000 ,ug, respectively (16) . Antide was about twice as active as analog 25. Table 8 shows a comparison of the oral activities of antide and four analogs. One was as active as antide, one was considerably less active, and two were less active at low doses (30 and 100 ,ug) and about as active at 300 ug.
After a 15-ng s.c. dose of [D-Qal(3)6]LHRH, the LH level rose to 91 + 4.6 ng/ml. At oral doses of 30, 100, and 300 ,ug of antide, reduced levels of LH of 75 + 3, 20 + 4, and 5 ± 1 ng/ml, respectively, were recorded. Analog 4, with Lys(Pic)5, D-Ala(PAC)6 showed no significant reduction of Table 7 . Oral activity of antide in the AOA assay Oral dose, AOA, ,ug o% inhibition* 0 (6/6) 300 18 (9/11) 600 73 (3/11) 1200 100 (0/11) The AOA assay was conducted in 10 mM acetic acid/water (1:1). *The number of rats that ovulated/total number of rats is given in parentheses.
Medical Sciences: Lj'ungqvist et al. The experimental design was as follows: - LH at 30 and 100 jig, but there was a reduction to 51 ± 6 ng/ml at 300 ,ug. Analog 12, with Lys(Pic)5, D-Lys(Pic)6, Ail7, and analog 6, with Lys(Pic)5, cis-D-Ala(PzAC)6, were less active than antide at 30 and 100 ,Ag but were equally active at 300 Ag. Both of these peptides were substantially more active than antide in the s.c. AOA assay. Analog 26 was equipotent with antide. This is not surprising since the only structural difference between these analogs is a pyrazine instead of a pyridine moiety in the N6-acyl group of the D-Lys6 residue. Table 8 also shows results with antide when 50 ng of the agonist was used. Comparison of these results with the data from the experiments using 15 ng of agonist shows a doseresponse relationship that is expected from competitive antagonism. In experiments that used 15 ng of agonist, 100 and 300 ,ug of antide reduced the LH level from 115 ± 15 ng/ml to 20 ± 4 and 5 + 1 ng/ml, respectively, whereas in experiments that used 50 ng of agonist, 300 and 900 ug of antide reduced the LH to the same level (19 ± 3 and 5.3 ± 1.2 ng/ml).
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